Novel Embolic Device Used for Arterial and Venous Tumor Treatments

Fluidx Medical Technology has announced successful patient use of the GPX Embolic Device to therapeutically devascularize, or block blood supply to, a tumor. The GPX Embolic Device is an innovative embolic designed to combine the benefits of other embolics like coils, particles, and liquids with simplified preparation, delivery, precision, and control leading to durable, long-term […]

Read More

Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Spectrum Solutions, LLC on January 27 announced it is sponsoring research in collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis. Spectrum has funded a study that aims to recruit 50 patients with lung cancer and seeks to validate saliva’s tumor-specific ctDNA detection sensitivity […]

Read More

Entrepreneur Your Startup – Get a Master’s Degree

Calling all life sciences early stage founders and startups! In partnership with the Lassonde Entrepreneur Institute at the University of Utah, the University’s David Eccles School of Business is now accepting applications to join its Master of Business Creation (MBC) program for 2021-2022. The priority application deadline is Feb. 12, 2021. This nine-month, professional-degree program […]

Read More

SDP Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes

  Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS). “The management of […]

Read More

Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

Based on its preliminary internal financial reporting for the fourth quarter 2020, Co-Diagnostics has announced that unaudited quarterly revenue for the company is anticipated to be the highest in the company’s history and to surpass analyst estimates. Analysts’ estimates for the fourth quarter ranged from $24 million to $25.98 million. Quarterly revenue is anticipated to […]

Read More

Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited;  Provides Corporate Update

Clene Nanomedicine, Inc. (Clene) last week announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update. Proceeds from this transaction totaled approximately $31.9 million. The combined, publicly traded company is operating under the name Clene Inc., and its common stock began trading on the NASDAQ Capital Market on […]

Read More

Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

Kidney care innovators Renalytix AI and DaVita are partnering on a new program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). This first of its kind program is expected to improve patient outcomes and provide meaningful cost reductions for healthcare providers and […]

Read More

Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform

Co-Diagnostics has announced that it has completed principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01. The new coronavirus strain comprises several mutations and may be more contagious than its predecessors. London and the southeast of Great Britain […]

Read More